Use of a composition in antiinflammation and cosmetics

Abstract

The application discloses application of a composition in anti-inflammation and cosmetics, and belongs to the technical field of cosmetics.The composition comprises hexapeptide-9 and lavender extract in a mass ratio of 10mg:10kg-1000mg:0.1kg.The composition can inhibit expression of inflammatory factors and has an anti-inflammatory effect.The cosmetics containing the composition have good anti-inflammatory effect.

Description

Technical Field

[0001] This invention relates to the field of cosmetic technology, and more specifically, to the application of a composition in anti-inflammatory purposes and related cosmetics. Background Technology

[0002] The efficacy of skincare products is a key focus for researchers and consumers. In the market, most cosmetics emphasize moisturizing, anti-wrinkle, and whitening effects, with new products offering multiple benefits such as moisturizing plus whitening, or moisturizing plus anti-aging. However, inflammation is also a common skin problem; therefore, anti-inflammatory products require further research and development and promotion.

[0003] In view of this, the present invention is proposed. Summary of the Invention

[0004] The purpose of this invention is to provide an application of the composition in anti-inflammatory and cosmetic applications to solve or improve the above-mentioned technical problems.

[0005] This application can be implemented as follows:

[0006] In a first aspect, this application provides the use of a composition in anti-inflammatory applications, the composition comprising hexapeptide-9 and lavender extract in a mass ratio of 10 mg:10 kg to 1000 mg:0.1 kg.

[0007] In an optional embodiment, the above composition is used to inhibit the expression of anti-inflammatory factors.

[0008] In an optional implementation, the anti-inflammatory factor includes at least one of TNF-α and IL-6.

[0009] In an optional embodiment, the composition, in addition to its anti-inflammatory properties, also promotes the expression of type I collagen, reduces transepidermal water loss, and / or increases the moisture content of the stratum corneum.

[0010] In an optional embodiment, the composition comprises hexapeptide-9 and lavender extract in a mass ratio of 100 mg:0.2 kg to 100 mg:3 kg.

[0011] In an optional embodiment, the lavender extract comprises 40 ppm to 50 ppm miRNA, 1 g / L to 3 g / L carbohydrates and 400 ppm to 900 ppm phenolic compounds; and / or, the amino acid composition of hexapeptide-9 is glycine-proline-glutamic acid-glycine-proline-glutamic acid.

[0012] In an optional implementation, the miRNA is 20 to 24 nucleotides in length.

[0013] In an optional embodiment, the lavender extract is extracted from Provence lavender.

[0014] In an optional embodiment, the method for preparing lavender extract includes: adding a chelating agent to a first mixture comprising lavender and water, and ultrasonically extracting it at 40°C to 50°C for 0.5 h to 1 h to obtain a second mixture, removing solids from the second mixture, and obtaining a filtrate.

[0015] In an optional embodiment, the chelating agent includes tetrasodium EDTA and / or inositol hexaphosphate.

[0016] In an optional embodiment, the pH of the first mixture is adjusted to 10-11 using an alkali before adding the chelating agent to the first mixture.

[0017] In an optional embodiment, after removing solids from the second mixture, the pH of the filtrate is adjusted to 6-7 using acid.

[0018] In optional embodiments, the polyphenol content per kg of composition is 400 mg to 1200 mg, and / or the miRNA content per kg of composition is 30 mg to 50 mg; and / or the pH value of the composition is 5.5 to 6.7.

[0019] Secondly, this application provides a cosmetic product whose raw materials include the composition used in any of the foregoing embodiments.

[0020] In an optional embodiment, the raw materials of the cosmetic also include excipients; the excipients include at least one of moisturizers, antioxidants, whitening and spot-removing agents, sunscreens, skin conditioning agents, emulsifiers, pH adjusters, acid-base buffers, chelating agents, thickeners, solubilizers, preservatives, and fragrances.

[0021] In an optional embodiment, the cosmetic raw materials include 0.2–0.4 wt% sodium polyacrylamide dimethyl taurate, 0.1–0.3 wt% polyacrylate crosspolymer-6, 1.5–2.5 wt% glycerin, 0.03–0.07 wt% sodium hyaluronate, 3–5 wt% 1,3-propanediol, 0.4–0.6 wt% cocoyl octanoate / caprylate, 0.4–0.6 wt% cyclopentamethoxysiloxane, 0.8–1.2 wt% 1,2-hexanediol, 0.3–0.5 wt% lactic acid bacteria fermentation product, and 0.8–1.2 wt% of the composition, with the balance being water.

[0022] In an optional embodiment, the cosmetic ingredients include 0.3 wt% sodium polyacrylamide dimethyl taurate, 0.2 wt% polyacrylate crosspolymer-6, 2 wt% glycerin, 0.05 wt% sodium hyaluronate, 4 wt% 1,3-propanediol, 0.5 wt% cocoyl octanoate / caprylate, 0.5 wt% cyclopentamethoxysiloxane, 1 wt% 1,2-hexanediol, 0.4 wt% lactic acid bacteria fermentation product, and 1 wt% of the composition, with the balance being water.

[0023] The beneficial effects of this application include:

[0024] The composition provided in this application comprises hexapeptide-9 and lavender extract in a specific ratio. This composition can inhibit the expression of inflammatory factors and exert an anti-inflammatory effect. Cosmetics containing the above composition have good anti-inflammatory effects. Attached Figure Description

[0025] To more clearly illustrate the technical solutions of the embodiments of the present invention, the accompanying drawings used in the embodiments will be briefly introduced below. It should be understood that the following drawings only show some embodiments of the present invention and should not be regarded as a limitation on the scope. For those skilled in the art, other related drawings can be obtained based on these drawings without creative effort.

[0026] Figure 1 This is a graph showing the effect of each experimental group in Test Example 1 of this application on the secretion of TNF-α by LPS-induced HaCaT cells;

[0027] Figure 2 This is a graph showing the effect of each experimental group in Test Example 1 of this application on LPS-induced IL-6 secretion by HaCaT cells;

[0028] Figure 3 This is an immunofluorescence image of COL-I protein expression in Test Example 2 of this application;

[0029] Figure 4 This is a graph showing the quantitative analysis results of dermal strength in Test Example 2 of this application. Detailed Implementation

[0030] To make the objectives, technical solutions, and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below. Where specific conditions are not specified in the embodiments, conventional conditions or conditions recommended by the manufacturer shall apply. Reagents or instruments whose manufacturers are not specified are all conventional products that can be purchased commercially.

[0031] The following is a detailed description of the application of the compositions provided in this application in anti-inflammatory and cosmetic applications.

[0032] This application provides the use of a composition in anti-inflammatory applications, the composition comprising hexapeptide-9 and lavender extract in a mass ratio of 10 mg:10 kg to 1000 mg:0.1 kg.

[0033] This composition can be used to inhibit the expression of anti-inflammatory factors, wherein the anti-inflammatory factors may, by way of example but not limited to, include at least one of TNF-α and IL-6. It can be understood that the above composition can inhibit the increase in TNF-α and / or IL-6 levels.

[0034] In addition to its anti-inflammatory properties, the above composition can also promote the expression of type I collagen, reduce transepidermal water loss, and / or increase the moisture content of the stratum corneum. Specifically, promoting the expression of type I collagen mainly involves regulating COL-I, thereby increasing the growth of type I collagen.

[0035] The above composition can be used in cosmetics to give the cosmetics the corresponding effects.

[0036] For reference, the mass ratio of hexapeptide-9 and lavender extract in the composition can be 100mg:0.01kg, 100mg:0.05kg, 100mg:0.1kg, 100mg:0.5kg, 100mg:1kg, 100mg:5kg, 100mg:10kg, 100mg:20kg, 100mg:30kg, 100mg:40kg, 100mg:50kg, 100mg:60kg, 100mg:70kg, 100mg:80kg, 100mg:90kg, or 100mg:100kg, or any other value within the range of 10mg:10kg to 1000mg:0.1kg (i.e., 100mg:100kg to 100mg:0.01kg).

[0037] In some typical embodiments, the composition comprises hexapeptide-9 and lavender extract in a mass ratio of 100mg:0.2kg to 100mg:3kg, such as hexapeptide-9 and lavender extract in mass ratios of 100mg:0.2kg, 100mg:0.5kg, 100mg:0.8kg, 100mg:1kg, 100mg:1.2kg, 100mg:1.5kg, 100mg:1.8kg, 100mg:2kg, 100mg:2.2kg, 100mg:2.5kg, 100mg:2.8kg, or 100mg:3kg.

[0038] In this application, the amino acid composition of hexapeptide-9 is glycine-proline-glutamic acid-glycine-proline-glutamic acid. The aforementioned hexapeptide-9 can be obtained directly by purchase or prepared by solid-phase synthesis or similar methods.

[0039] For reference, the following method is provided for preparing the above-mentioned hexapeptide-9: Using Fmoc-protected amino acids and amino resin as raw materials, 3 mmol of Fmoc-Gly, 3 mmol of 1-hydroxy-benzotriazole, 3.3 mmol of dicyclohexylcarbodiimide, 20 mg of 4-N,N'-dimethylaminopyridine, 8 mL of DMF, and 7 mL of dichloromethane are added to 1 mmol of activated amino resin. The mixture is reacted for 30 min, washed, and vacuum dried to obtain Fmoc-Gly-resin. 0.1 mmol of the obtained Fmoc-Gly-resin is weighed, and the following process is repeated: 0.1 mmol of Fmoc-amino acid-resin is weighed, 5 mL of deprotection solution (20 wt% piperidine / DMF) is added, washed, 0.3 mmol of Fmoc-amino acid is added, the mixture is reacted for 30 min, washed, and vacuum dried. Fmoc-Pro, Fmoc-Gln, Fmoc-Gly, Fmoc-Pro, and Fmoc-Gln are sequentially linked. After the reaction was completed, the sample was washed and dried. 5 mL of cutting fluid (75 wt% trifluoroacetic acid, 15 wt% ethylenedithiol, 5 wt% phenol and 5 wt% water) was added, and the mixture was stirred for 90 min. After centrifugation, the filtrate was purified by reversed-phase high-performance liquid chromatography to obtain hexapeptide with a purity of over 95%, which was then prepared into an aqueous solution of 100 ppm hexapeptide.

[0040] In this application, the lavender extract includes 40 ppm to 50 ppm (e.g., 40 ppm, 42 ppm, 45 ppm, 48 ppm, or 50 ppm) of miRNA, 1 g / L to 3 g / L (e.g., 1 g / L, 1.5 g / L, 2 g / L, 2.5 g / L, or 3 g / L), and 400 ppm to 900 ppm (e.g., 400 ppm, 500 ppm, 600 ppm, 700 ppm, 800 ppm, or 900 ppm). The miRNA is 20 to 24 nucleotides in length.

[0041] Similarly, the lavender extract described above can be obtained directly by purchasing or prepared at home. For example, the lavender extract can be extracted from Provence lavender, a variety that has higher water content and better drought resistance compared to other lavender varieties.

[0042] For reference, the following is a method for preparing the above-mentioned lavender extract: a chelating agent is added to a first mixture comprising lavender and water, and the mixture is ultrasonically extracted at 40°C to 50°C for 0.5 h to 1 h to obtain a second mixture. The solids in the second mixture are removed to obtain a filtrate.

[0043] In some embodiments, the pH of the first mixture may be adjusted to 10-11 using an alkali before adding the chelating agent. The mass percentage of lavender in the first mixture may be 1 wt% to 10 wt%.

[0044] Chelating agents may include tetrasodium EDTA and / or inositol hexaphosphate. Ultrasonic extraction temperatures may be 40℃, 41℃, 42℃, 43℃, 44℃, 45℃, 46℃, 47℃, 48℃, 49℃, or 50℃, and ultrasonic extraction times may be 0.5h, 0.6h, 0.7h, 0.8h, 0.9h, or 1h.

[0045] Solids in the second mixture can be removed, for example, by centrifugation at a speed of 3000–8000 rpm for a time of 10–30 min.

[0046] After removing solids from the second mixture, the pH of the filtrate is adjusted to 6-7 using acid. This step allows the lavender extract to be directly applied to cosmetics.

[0047] Finally, the filtrate was filtered through a 0.2μm filter membrane to obtain a clear filtrate, which is the lavender extract.

[0048] In some typical embodiments, the composition provided in this application contains 400 mg to 1200 mg of polyphenols (more preferably 490 mg to 500 mg) and 30 mg to 50 mg of miRNA per kg of composition (more preferably 38 mg to 40 mg). The pH value of the composition (20°C, 1%) is 5.5 to 6.7 (more preferably around 6.3).

[0049] In addition, this application also provides a cosmetic product whose raw materials include the above-mentioned composition.

[0050] The raw materials of the aforementioned cosmetics may also include excipients; excipients may include, but are not limited to, at least one of the following: moisturizers, antioxidants, whitening agents, sunscreens, skin conditioning agents, emulsifiers, pH adjusters, acid-base buffers, chelating agents, thickeners, solubilizers, preservatives, and fragrances.

[0051] In some embodiments, the cosmetic ingredients include 0.2–0.4 wt% sodium polyacrylamide dimethyl taurate, 0.1–0.3 wt% polyacrylate crosspolymer-6, 1.5–2.5 wt% glycerin, 0.03–0.07 wt% sodium hyaluronate, 3–5 wt% 1,3-propanediol, 0.4–0.6 wt% cocoyl octanoate / caprylate, 0.4–0.6 wt% cyclopentamethoxysiloxane, 0.8–1.2 wt% 1,2-hexanediol, 0.3–0.5 wt% lactic acid bacteria fermentation product, and 0.8–1.2 wt% of the composition, with the balance being water.

[0052] In some typical embodiments, the raw materials of the above-mentioned cosmetic include 0.3 wt% sodium polyacrylamide dimethyl taurate, 0.2 wt% polyacrylate crosspolymer-6, 2 wt% glycerin, 0.05 wt% sodium hyaluronate, 4 wt% 1,3-propanediol, 0.5 wt% cocoyl octanoate / caprylate, 0.5 wt% cyclopentamethoxysiloxane, 1 wt% 1,2-hexanediol, 0.4 wt% lactic acid bacteria fermentation product, and 1 wt% of the composition, with the balance being water.

[0053] All of the above-mentioned raw materials can be purchased directly.

[0054] In preparation, water, sodium polyacrylamide dimethyl taurate, polyacrylate crosspolymer-6, glycerol, sodium hyaluronate, and 1,3-propanediol are mixed and heated to 75-85°C, and stirred to dissolve (e.g., 25-35 r / min, 4-6 min) to obtain a first mixture; coconut oil alcohol-octanoate / decanoate and cyclopentamethoxysiloxane are added to the first mixture and homogenized (e.g., 2800-3200 r / min, 4-6 min) to obtain a second mixture; the mixture is cooled to 35-40°C, and 1,2-hexanediol, lactic acid bacteria fermentation products, and the composition of this application are added, stirred (e.g., 28-32 r / min, 6-10 min) until homogeneous, and then cooled to room temperature.

[0055] For reference, the dosage forms of cosmetics in this application may include, for example, creams, lotions, liquids, gels, powders, clays, wax-based products, sprays, aerosols, patches, or films (including substrates), and may also be any other applicable dosage forms of cosmetics that act directly or indirectly on the skin. For example, they may be, for instance, whitening serums, moisturizing serums, sunscreen serums, anti-wrinkle serums, toners, lotions, makeup removers, cleansing milks, moisturizing creams, sunscreens, sunblocks, sunscreen lotions, body lotions, cold creams, moisturizing creams, day creams, night creams, moisturizing gels, face masks, facial cleansers, facial foams, facial washes, foundations, hand creams, shower gels, cosmetic soaps, bar soaps, setting sprays, or moisturizing sprays, etc.

[0056] The features and performance of the present invention will be further described in detail below with reference to embodiments.

[0057] Example 1

[0058] This embodiment provides a composition obtained by mixing 100 mg of hexapeptide-9 and 2 kg of lavender extract at room temperature and stirring at 200 rpm until homogeneous.

[0059] The lavender extract was prepared by the following method: 50g of the aerial parts of Provence lavender were dried and pulverized, and then mixed with 950mL of deionized water to prepare a 5wt% first mixture. The pH of the first mixture was adjusted to 10.5 with alkali, and 10mM of tetrasodium EDTA was added. The mixture was ultrasonically extracted at 50℃ for 1 hour to obtain a second mixture. The second mixture was centrifuged at 4000rpm for 10min to remove solids and obtain a filtrate. The pH of the filtrate was then adjusted to 6.3 with acid. Finally, the filtrate was filtered through a 0.2μm filter membrane to obtain a clear filtrate, which is the lavender extract without essential oil components.

[0060] Hexapeptide-9 was prepared by the following method: using Fmoc-protected amino acids and amino resin as raw materials, 3 mmol of Fmoc-Gly, 3 mmol of 1-hydroxy-benzotriazole, 3.3 mmol of dicyclohexylcarbodiimide, 20 mg of 4-N,N'-dimethylaminopyridine, 8 mL of DMF, and 7 mL of dichloromethane were added to 1 mmol of activated amino resin. The reaction was carried out for 30 min, washed, and vacuum dried to obtain Fmoc-Gly-resin. 0.1 mmol of the obtained Fmoc-Gly-resin was weighed, and the following process was repeated: 0.1 mmol of Fmoc-amino acid-resin was weighed, 5 mL of deprotection solution (20 wt% piperidine / DMF) was added, washed, 0.3 mmol of Fmoc-amino acid was added, the reaction was carried out for 30 min, washed, and vacuum dried. Fmoc-Pro, Fmoc-Gln, Fmoc-Gly, Fmoc-Pro, and Fmoc-Gln were sequentially linked. After the reaction was completed, the sample was washed and dried. 5 mL of cutting fluid (75 wt% trifluoroacetic acid, 15 wt% ethylenedithiol, 5 wt% phenol and 5 wt% water) was added, and the mixture was stirred for 90 min. After centrifugation, the filtrate was purified by reversed-phase high-performance liquid chromatography to obtain hexapeptide with a purity of over 95%, which was then prepared into an aqueous solution of 100 ppm hexapeptide.

[0061] The composition contains 500 mg of polyphenols, 40 mg of miRNA, and a pH value (20°C, 1%) of 6.3 per kg.

[0062] Example 2

[0063] The difference between this embodiment and Example 1 is that the composition was obtained by mixing 100 mg of hexapeptide-9 and 0.5 kg of lavender extract at room temperature.

[0064] The composition contains 500 mg of polyphenols, 40 mg of miRNA, and a pH value (20°C, 1%) of 6.3 per kg.

[0065] Example 3

[0066] The difference between this embodiment and Example 1 is that the composition was obtained by mixing 100 mg of hexapeptide-9 and 0.2 kg of lavender extract at room temperature.

[0067] The composition contains 500 mg of polyphenols, 40 mg of miRNA, and a pH value (20°C, 1%) of 6.3 per kg.

[0068] Example 4

[0069] The difference between this embodiment and Example 1 is that the composition was obtained by mixing 100 mg of hexapeptide-9 and 3 kg of lavender extract at room temperature.

[0070] The composition contains 500 mg of polyphenols, 40 mg of miRNA, and a pH value (20°C, 1%) of 6.3 per kg.

[0071] Example 5

[0072] The difference between this embodiment and Example 1 is that the composition was obtained by mixing 100 mg of hexapeptide-9 and 0.01 kg of lavender extract at room temperature.

[0073] The composition contains 495 mg of polyphenols, 39 mg of miRNA, and a pH value (20°C, 1%) of 6.3 per kg.

[0074] Example 6

[0075] The difference between this embodiment and Example 1 is that the composition is obtained by mixing 100 mg of hexapeptide-9 and 100 kg of lavender extract at room temperature.

[0076] The composition contains 500 mg of polyphenols, 40 mg of miRNA, and a pH value (20°C, 1%) of 6.3 per kg.

[0077] Example 7

[0078] This embodiment provides a serum in which the composition prepared in Example 1 is present at a concentration of 1%. The raw material composition of the serum is shown in Table 1.

[0079] Table 1 Raw Material Composition

[0080]

[0081] The preparation method of the above-mentioned serum is as follows:

[0082] S1: Add phase A to the emulsification pot, mix and heat to 80°C, stir and dissolve (30 rpm, 5 min) to obtain the first mixture;

[0083] S2: Add phase B to the first mixture and homogenize (3000 rpm, 5 min) to obtain the second mixture;

[0084] S3: Stir the second mixture and cool it to 40°C. Add the C phase component and stir (30 rpm for 8 minutes) until homogeneous. Cool to room temperature.

[0085] Example 8

[0086] The difference between this embodiment and embodiment 7 is that the raw material composition of the essence is shown in Table 2.

[0087] Table 2 Raw Material Composition

[0088]

[0089] Example 9

[0090] The difference between this embodiment and embodiment 7 is that the raw material composition of the essence is shown in Table 3.

[0091] Table 3 Raw Material Composition

[0092]

[0093] Test Example 1

[0094] Inhibitory effect of the composition on inflammatory factors

[0095] HaCaT cells grown in complete KSFM medium and in the logarithmic growth phase were seeded at 10,000 cells / well in 96-well plates and incubated at 37°C in a 5% CO2 incubator. After 3 days of culture, active ingredients prepared with complete culture medium (the active ingredients included four types: the first was the composition prepared in Example 1: 1% mixture (where 1% refers to the mass percentage of the active substance in the reaction system); the second was a composition with the hexapeptide-9 and lavender extract ratios interchanged in Example 1: 1% mixture X; the third was only 1% hexapeptide-9; and the fourth was only 1% lavender extract) were added. A blank control group was added, and an untreated group was also included. After incubation for another 24 hours, the levels of TNF-α and IL-6 in the cells of each group were detected using an ELISA kit. The results are shown below. Figure 1 and Figure 2 As shown.

[0096] like Figure 1 As shown, compared with the untreated group, the protein content of TNF-α in keratinocytes in the modeling blank group increased by 5.03 times (P < 0.001), indicating successful modeling. Compared with the modeling blank group, the inhibition rates of TNF-α by 1% hexapeptide-9 and 1% lavender extract were 11.3% (P < 0.05) and 6.2%, respectively. When the two were mixed in the proportions of Example 1, the inhibition rate of TNF-α by the 1% mixture increased to 63.4% (P < 0.001). However, after interchangeing the ratios of hexapeptide-9 and lavender extract, the inhibition rate of TNF-α by the 1% mixture X was only 11.1% (P < 0.05).

[0097] like Figure 2 As shown, compared with the untreated group, the protein content of IL-6 in keratinocytes in the modeling blank group increased by 10.7 times (P < 0.001), indicating successful modeling. Compared with the modeling blank group, the inhibition rates of IL-6 by 1% hexapeptide-9 and 1% lavender extract were 7.2% (P < 0.05) and 14.4% (P < 0.05), respectively. When the two were mixed in the proportions of Example 1, the inhibition rate of IL-6 by the 1% mixture increased to 52.4% (P < 0.001). However, after the ratios of hexapeptide-9 and lavender extract were interchanged, the inhibition rate of IL-6 by the 1% mixture X was only 10.6% (P < 0.05).

[0098] The above results indicate that hexapeptide-9 and lavender extract, when combined in a specific ratio, have a synergistic effect in anti-inflammatory efficacy.

[0099] Test Example 2

[0100] The regulatory effect of the composition on type I collagen

[0101] COL-I was detected using ex vivo skin. Ex vivo skin samples were cultured in a culture medium, and then either the composition prepared in Example 1 (1 wt%) or a positive control (50 ng / mL TGF-β) was added. A blank control group (Control group) without any treatment was also included. The samples were incubated for 48 hours. After incubation, the tissues were fixed in OCT fixative and stored at -80°C to form frozen tissue blocks. The frozen tissue blocks were then sectioned using a cryostat. COL-I was added to the sectioned tissues, and images of each group were taken. The fluorescence intensity of the images was calculated and analyzed using software. The results are shown below. Figure 3 and Figure 4 As shown.

[0102] Depend on Figure 3 and Figure 4It can be seen that the positive control results prove the reliability of the test model; compared with the blank control group, the fluorescence intensity of collagen I after treatment with the composition prepared in Example 1 was significantly enhanced, and the intensity of the dermal layer was significantly increased. A 1% concentration of the composition can significantly increase the growth of type I collagen.

[0103] Test Example 3

[0104] Serum stability test

[0105] The essence prepared in Example 7 was subjected to stability tests such as heat resistance, cold resistance, alternation, and light exposure.

[0106] The heat resistance test conditions were: 45±1℃, constant temperature and protection from light, for 30 days;

[0107] The cold resistance test conditions were: -20±1℃, constant temperature and protection from light, for 30 days;

[0108] The alternating test conditions are: -20℃ constant temperature for 3 days, then 25℃ constant temperature for 1 day, then 45℃ constant temperature for 3 days, in the dark;

[0109] The light exposure test conditions were: a constant temperature and humidity light exposure test chamber (1.47 × 10⁻⁶). 6 Lux·hr), 30d;

[0110] The test results are shown in Table 4.

[0111] Table 4 Product Stability Test

[0112] Heat resistant Cold-resistant Alternation illumination serum No abnormalities No abnormalities No abnormalities No abnormalities

[0113] As can be seen from Table 4, the composition prepared in Example 1 of this application can be used to prepare serum and has excellent stability.

[0114] Test Example 4

[0115] stratum corneum moisture content and transepidermal water loss

[0116] Test sample: The essence prepared in Example 3.

[0117] Test environment: Temperature 21±1℃, relative humidity 50±10%RH constant temperature and humidity zone.

[0118] Test method:

[0119] A total of 28 volunteers, aged 42.64 ± 8.58 years, with Asian skin, were selected for testing. Participants cleansed their faces using a standardized facial cleanser and sat quietly in a temperature- and humidity-controlled waiting area for 30 minutes. Researchers used a Comeometer CM 825 and a Tewameter TM300 to collect initial values ​​(before sample use) of the stratum corneum moisture content and transepidermal water loss (TEWL) on the participants' cheek areas. After cleansing, participants applied an appropriate amount of product evenly to their faces and massaged it until absorbed. The product was used twice daily, morning and evening, for 56 days. Participants were followed up on days 28 and 56 of product use. Their faces were cleansed again, and they sat quietly in the temperature- and humidity-controlled waiting area for 30 minutes. The stratum corneum moisture content and TEWL on the participants' cheek areas were collected on days 28 and 56.

[0120] A higher Corneometer Unit (CU) value indicates a higher water content in the stratum corneum; transepidermal water loss rate (g / h / m) 2 The lower the value, the less transepidermal water loss per unit time and per unit cross-section.

[0121] Rate of change = (Measurement after use - Measurement before use) / Measurement before use × 100%.

[0122] The results are shown in Table 5.

[0123] Table 5 Test Results

[0124] D0 D28 D56 rate of change D28 rate of change D56 Skin stratum corneum moisture content (CU) 52.04 57.06 59.12 11.96％ 15.96％ <![CDATA[Transdermal water loss rate (g / h / m 2 )]]> 13.25 12.33 12.34 -5.34％ -4.69％

[0125] As shown in Table 5, compared with before use, after 28 days and 56 days of using the essence prepared in Example 7, the skin stratum corneum moisture content of the subjects increased significantly by 11.96% and 15.96%, respectively; and the transepidermal water loss rate decreased significantly by 5.34% and 4.69%.

[0126] Test Example 5

[0127] Skin elasticity test

[0128] Test sample: The serum prepared according to Example 7.

[0129] Test environment: Temperature 21±1℃, relative humidity 50±10%RH constant temperature and humidity zone.

[0130] Test method:

[0131] A total of 28 volunteers, aged 42.64 ± 8.58 years, with Asian skin, were selected for testing. Participants cleansed their faces using a standardized facial cleanser and sat quietly in a temperature- and humidity-controlled waiting area for 30 minutes. The testing personnel used a Cutometer MPA580 elasticity meter to collect initial values ​​of the participants' cheek areas (before sample use). After cleansing, participants applied an appropriate amount of product evenly to their faces and massaged it until absorbed. The product was used twice daily, morning and evening, for a period of 56 days. Participants were followed up on days 28 and 56 of product use. Their faces were cleansed again, and they sat quietly in the temperature- and humidity-controlled waiting area for 30 minutes to collect elasticity data of their cheek areas (D28 / D56).

[0132] R2 represents the ratio of skin elasticity without negative pressure to maximum stretching under negative pressure. The closer R2 is to 1, the better the skin elasticity.

[0133] R5 represents the ratio of the elastic portion of the skin during the recovery process to the elastic portion during the negative pressure process in the first cycle of the skin test. The closer R5 is to 1, the better the skin elasticity.

[0134] Rate of change = (Measurement after use - Measurement before use) / Measurement before use × 100%.

[0135] The results are shown in Table 6.

[0136] Table 6 Test Results

[0137] D0 D28 D56 rate of change D28 rate of change D56 R2 0.7948 0.8321 0.8268 5.17％ 4.26％ R5 0.6974 0.7793 0.7877 13.83％ 14.23％

[0138] As shown in Table 6, compared with before use, after 28 days and 56 days of using the serum prepared in Example 7, the subjects' skin elasticity index R2 increased significantly by 5.17% and 4.26%, respectively; and R5 increased significantly by 13.83% and 14.23%, respectively.

[0139] Test Example 6

[0140] Skin wrinkle test

[0141] The testing method was the same as in Test Example 5. Primos-CR images were collected from specific areas of the volunteers' faces before sample use (D0), 28 days after use (D28), and 56 days after use (D56). The analysis results are shown in Table 7.

[0142] Rate of change = (Measurement after use - Measurement before use) / Measurement before use × 100%.

[0143] Table 7 Test Results

[0144] D0 D28 D56 rate of change D28 rate of change D56 Wrinkle count 27.29 16.39 14.32 -41.05％ -45.59％ wrinkle area 156.67 147.66 148.89 -6.53％ -5.79％

[0145] As shown in Table 7, compared with before use, after 28 days and 56 days of using the serum prepared in Example 7, the number of wrinkles on the subjects' skin was significantly reduced by 41.05% and 45.59%, respectively; the wrinkle area was significantly reduced by 6.53% and 5.79%, respectively.

[0146] In summary, the composition provided in this application, obtained from hexapeptide-9 and lavender extract in a specific ratio, can inhibit the expression of inflammatory factors and exert an anti-inflammatory effect. Cosmetics containing the above composition have good anti-inflammatory effects.

[0147] The above are merely preferred embodiments of the present invention and are not intended to limit the present invention. Various modifications and variations can be made to the present invention by those skilled in the art. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of the present invention should be included within the scope of protection of the present invention.

Claims

1. The use of a composition in the preparation of an anti-inflammatory product, characterized in that, The composition comprises hexapeptide-9 and lavender extract in a mass ratio of 10 mg:10 kg to 1000 mg:0.1 kg; The composition is used to inhibit the expression of anti-inflammatory factors, including at least one of TNF-α and IL-6; The lavender extract comprises 40 ppm to 50 ppm miRNA, 1 g / L to 3 g / L carbohydrates and 400 ppm to 900 ppm phenolic compounds; the miRNA has a length of 20 to 24 nucleotides; the amino acid composition of the hexapeptide-9 is glycine-proline-glutamic acid-glycine-proline-glutamic acid. The composition contains 400 mg to 1200 mg of polyphenols per kg and 30 mg to 50 mg of miRNA per kg; the composition has a pH value of 5.5 to 6.

7.

2. The application according to claim 1, characterized in that, The composition, in addition to its anti-inflammatory properties, also promotes the expression of type I collagen, reduces transepidermal water loss, and / or increases the moisture content of the stratum corneum.

3. The application according to claim 1 or 2, characterized in that, The composition comprises the hexapeptide-9 and the lavender extract in a mass ratio of 100 mg:0.2 kg to 100 mg:3 kg.

4. The application according to claim 1, characterized in that, The lavender extract is derived from Provence lavender.

5. The application according to claim 1, characterized in that, The method for preparing the lavender extract includes: adding a chelating agent to a first mixture comprising lavender and water, and ultrasonically extracting it at 40℃~50℃ for 0.5h~1h to obtain a second mixture, removing the solids in the second mixture, and obtaining a filtrate.

6. The application according to claim 5, characterized in that, The chelating agent includes tetrasodium EDTA and / or inositol hexaphosphate.

7. The application according to claim 5, characterized in that, Before adding the chelating agent to the first mixture, the pH of the first mixture is adjusted to 10-11 using an alkali.

8. The application according to claim 5, characterized in that, After removing solids from the second mixture, the pH of the filtrate is adjusted to 6-7 using acid.

Images